Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis
NCT00432757 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2009-04-09
Summary
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy drug with a contact lens compared to placebo in preventing ocular itching associated with allergic conjunctivitis
Conditions
- Allergic Conjunctivitis
Interventions
- DRUG
-
Ketotifen with a Contact Lens (generic name not yet established)
Sponsors & Collaborators
-
Vistakon Pharmaceuticals
lead INDUSTRY
Principal Investigators
-
Brian Pall, OD, MS, FAAO · Vistakon Pharmaceuticals
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 8 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-01-31
- Completion
- 2007-03-31
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
NCT00244543 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
NCT00836485 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
NCT01732757 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
NCT05579730 ·Status: COMPLETED ·Phase: PHASE3
-
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
NCT00770133 ·Status: COMPLETED ·Phase: PHASE3
-
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
NCT02308501 ·Status: COMPLETED ·Phase: PHASE4
-
Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers
NCT00223951 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
NCT01332188 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.
NCT00769886 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
NCT05815758 ·Status: COMPLETED ·Phase: PHASE3
-
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
NCT01881113 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers
NCT01159015 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of a Eye Drop for Eye Allergy
NCT00889330 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis
NCT01258309 ·Status: COMPLETED ·Phase: PHASE3
-
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
NCT01107405 ·Status: COMPLETED ·Phase: PHASE2
-
A Multi-Center Study Evaluating the Safety of AC-170 0.24%
NCT02132169 ·Status: COMPLETED ·Phase: PHASE3
-
Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis
NCT01860664 ·Status: TERMINATED ·Phase: PHASE2
-
DEXTENZA Therapy for Treatment of Allergic Conjunctivitis
NCT04708821 ·Status: COMPLETED ·Phase: PHASE4
-
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
NCT03489941 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
NCT00689078 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis
NCT00423007 ·Status: COMPLETED ·Phase: PHASE3
-
Systemic Pharmacokinetics of BOL-303224-A
NCT00407589 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
NCT04050865 ·Status: COMPLETED ·Phase: PHASE3
-
Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
NCT01363700 ·Status: COMPLETED ·Phase: PHASE3
-
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
NCT01685242 ·Status: COMPLETED ·Phase: PHASE3